Cerus Corporation

DB:CU2 Stock Report

Market Cap: €309.4m

Cerus Valuation

Is CU2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CU2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CU2's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CU2's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CU2?

Key metric: As CU2 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CU2. This is calculated by dividing CU2's market cap by their current revenue.
What is CU2's PS Ratio?
PS Ratio1.9x
SalesUS$176.23m
Market CapUS$326.86m

Price to Sales Ratio vs Peers

How does CU2's PS Ratio compare to its peers?

The above table shows the PS ratio for CU2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
PHH2 Paul Hartmann
0.3xn/a€745.9m
SBS Stratec
1.5x7.7%€382.3m
PUS PULSION Medical Systems
3.7xn/a€134.4m
M12 M1 Kliniken
0.9x8.2%€302.4m
CU2 Cerus
1.9x10.7%€326.9m

Price-To-Sales vs Peers: CU2 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (1.6x).

Price to Sales Ratio vs Industry

How does CU2's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$834.58m
PHH2 Paul Hartmann
0.3xn/aUS$788.03m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
CU2 1.9xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CU2 is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Medical Equipment industry average (3.6x).

Price to Sales Ratio vs Fair Ratio

What is CU2's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CU2 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: CU2 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CU2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.66
€3.59
+116.4%
26.1%€4.60€2.30n/a5
Nov ’25€1.42
€3.59
+151.8%
26.1%€4.60€2.30n/a5
Oct ’25€1.54
€4.12
+168.1%
26.3%€5.50€2.29n/a5
Sep ’25€2.04
€4.12
+102.1%
26.3%€5.50€2.29n/a5
Aug ’25€2.06
€4.13
+100.0%
26.3%€5.50€2.29n/a5
Jul ’25€1.61
€4.09
+153.2%
30.8%€5.57€1.86n/a5
Jun ’25€1.67
€4.09
+145.2%
30.8%€5.57€1.86n/a5
May ’25€1.61
€3.94
+144.8%
35.0%€5.63€1.88n/a5
Apr ’25€1.62
€3.80
+133.8%
34.7%€5.52€2.30n/a4
Mar ’25€1.99
€4.26
+114.1%
26.7%€5.48€2.74n/a3
Feb ’25€1.66
€4.26
+157.2%
26.7%€5.48€2.74n/a3
Jan ’25€2.08
€3.85
+85.3%
34.7%€5.60€2.33n/a4
Dec ’24€1.46
€3.85
+164.1%
34.7%€5.60€2.33n/a4
Nov ’24€1.31
€5.28
+302.4%
41.4%€8.44€2.34€1.424
Oct ’24€1.46
€5.23
+256.8%
37.7%€8.18€2.73€1.544
Sep ’24€1.72
€5.23
+203.6%
37.7%€8.18€2.73€2.044
Aug ’24€2.77
€6.92
+150.0%
40.8%€10.43€2.72€2.064
Jul ’24€2.21
€6.92
+212.9%
40.8%€10.43€2.72€1.614
Jun ’24€1.97
€6.92
+250.6%
40.8%€10.43€2.72€1.674
May ’24€2.05
€7.04
+244.0%
39.3%€10.54€2.98€1.614
Apr ’24€2.54
€7.27
+186.1%
37.8%€10.79€3.28€1.624
Mar ’24€2.59
€7.27
+181.1%
37.8%€10.79€3.28€1.994
Feb ’24€2.84
€7.24
+154.9%
39.5%€10.66€3.47€1.664
Jan ’24€3.29
€8.69
+163.9%
26.1%€11.49€5.99€2.085
Dec ’23€3.77
€8.69
+130.6%
26.1%€11.49€5.99€1.465
Nov ’23€3.70
€9.31
+152.0%
21.0%€11.77€6.14€1.315

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

1.0%

1Y

-34.2%

LNA Santé

€234.2m

Engages in the management and operation of health establishments.

2N3

€22.30

7D

-4.9%

1Y

16.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%